P F Lin

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. ncbi Stavudine resistance: an update on susceptibility following prolonged therapy
    P F Lin
    Bristol Myers Squibb, Wallingford, Conn, USA
    Antivir Ther 4:21-8. 1999
  2. ncbi A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding
    H G H Wang
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Curr Pharm Des 10:1785-93. 2004

Collaborators

Detail Information

Publications2

  1. ncbi Stavudine resistance: an update on susceptibility following prolonged therapy
    P F Lin
    Bristol Myers Squibb, Wallingford, Conn, USA
    Antivir Ther 4:21-8. 1999
    ..This low incidence of stavudine resistance is in striking contrast to that observed with other nucleoside analogues and further supports the use of stavudine in first-line combination therapy for HIV patients...
  2. ncbi A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding
    H G H Wang
    Department of Virology, Bristol Myers Squibb Pharmaceutical Research Institute, Wallingford, CT 06492, USA
    Curr Pharm Des 10:1785-93. 2004
    ..Together, the data show that BMS-378806 is the first of a new class of HIV inhibitors with the potential to become a valued addition to our current repertoire of antiretroviral drugs...